GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Net Income (Continuing Operations)

Scancell Holdings (FRA:SCP) Net Income (Continuing Operations) : €-10.87 Mil (TTM As of Oct. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Scancell Holdings's Net Income (Continuing Operations) for the six months ended in Oct. 2023 was €-2.94 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Oct. 2023 was €-10.87 Mil.


Scancell Holdings Net Income (Continuing Operations) Historical Data

The historical data trend for Scancell Holdings's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Net Income (Continuing Operations) Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.52 -6.29 -17.92 -5.47 -13.56

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.79 -9.32 -5.70 -7.93 -2.94

Scancell Holdings Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-10.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings  (FRA:SCP) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Scancell Holdings Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (FRA:SCP) Business Description

Industry
Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines